Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26

Benzinga · 3d ago
Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.